pills-istock-525984851
sprng23 / iStockphoto.com
28 April 2017Biotechnology

Merck to divest biosimilars arm to Fresenius Kabi

Merck will divest its biosimilars business to Fresenius Kabi in order to focus on innovative drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk